Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, New York
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Feb 2003

Description:

Patients: This Phase II study involved 54 patients with metastatic renal cell carcinoma; 44 men and 10 women. The average age was 59. Thirty-seven patients had undergone a prior nephrectomy. The average time from time of original diagnosis to the start of this treatment was 22.5 months.

Treatment: The treatment consisted of the administration of Cetuximab, a monoclonal antibody.

Toxicity: Grade 3-4 toxicities included asthenia, back pain, heart failure, anemia, lung edema, acne, skin rash, and dry skin.

Results: There were no complete or partial responses.

Correspondence: Robert J. Motzer, MD




Back